The 21st Century Cures Act, passed in 2016, places additional focus on using these data types to support regulatory decision-making, including approval of new indications for approved drugs. Accordingly, Congress defined RWE as data regarding the usage, or the potential benefits or risks, of a drug derived from sources other than traditional clinical trials. FDA has expanded on this definition as discussed here.

Read the complete statement here: Real-World Evidence | FDA